FibroGen, Inc (NASDAQ:FGEN) – Research analysts at Jefferies Group raised their FY2017 earnings per share estimates for FibroGen in a note issued to investors on Wednesday. Jefferies Group analyst M. Yee now forecasts that the biopharmaceutical company will post earnings per share of ($1.75) for the year, up from their prior estimate of ($1.98). Jefferies Group currently has a “Buy” rating and a $75.00 price target on the stock. Jefferies Group also issued estimates for FibroGen’s Q4 2017 earnings at ($0.29) EPS, Q1 2018 earnings at ($0.48) EPS, Q2 2018 earnings at ($0.51) EPS, Q3 2018 earnings at ($0.53) EPS, Q4 2018 earnings at $0.66 EPS and FY2018 earnings at ($0.86) EPS.
TRADEMARK VIOLATION NOTICE: “FY2017 EPS Estimates for FibroGen, Inc Boosted by Jefferies Group (FGEN)” was published by Markets Daily and is owned by of Markets Daily. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.themarketsdaily.com/2017/11/15/fy2017-eps-estimates-for-fibrogen-inc-boosted-by-jefferies-group-fgen.html.
A number of other brokerages have also recently issued reports on FGEN. Mizuho began coverage on FibroGen in a research note on Wednesday, October 4th. They set a “neutral” rating and a $61.00 price objective on the stock. Stifel Nicolaus reaffirmed a “buy” rating and set a $80.00 price objective on shares of FibroGen in a research note on Thursday, September 14th. William Blair reaffirmed an “outperform” rating on shares of FibroGen in a research note on Wednesday, August 9th. Goldman Sachs Group, Inc. (The) cut FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price objective on the stock. in a research note on Friday, July 21st. Finally, BidaskClub cut FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $65.67.
FibroGen (NASDAQ FGEN) opened at $44.85 on Monday. FibroGen has a 12 month low of $19.25 and a 12 month high of $60.15. The company has a debt-to-equity ratio of 0.16, a quick ratio of 10.83 and a current ratio of 10.83.
A number of institutional investors and hedge funds have recently modified their holdings of FGEN. UBS Asset Management Americas Inc. purchased a new stake in FibroGen in the first quarter worth about $288,000. Parametric Portfolio Associates LLC purchased a new stake in FibroGen in the first quarter worth about $249,000. Principal Financial Group Inc. lifted its holdings in FibroGen by 0.4% in the first quarter. Principal Financial Group Inc. now owns 136,045 shares of the biopharmaceutical company’s stock worth $3,354,000 after buying an additional 504 shares during the period. Wellington Management Group LLP lifted its holdings in FibroGen by 55.6% in the first quarter. Wellington Management Group LLP now owns 87,031 shares of the biopharmaceutical company’s stock worth $2,146,000 after buying an additional 31,105 shares during the period. Finally, Teachers Advisors LLC lifted its holdings in FibroGen by 1.4% in the first quarter. Teachers Advisors LLC now owns 468,413 shares of the biopharmaceutical company’s stock worth $11,546,000 after buying an additional 6,512 shares during the period. Institutional investors and hedge funds own 46.93% of the company’s stock.
In other FibroGen news, insider K Peony Yu sold 7,500 shares of the firm’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $55.37, for a total value of $415,275.00. Following the completion of the sale, the insider now directly owns 170,104 shares in the company, valued at $9,418,658.48. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jorma Routti sold 12,000 shares of the firm’s stock in a transaction dated Friday, September 1st. The stock was sold at an average price of $47.36, for a total transaction of $568,320.00. Following the completion of the sale, the director now owns 133,840 shares of the company’s stock, valued at $6,338,662.40. The disclosure for this sale can be found here. Insiders sold 428,118 shares of company stock worth $22,355,896 over the last three months. 14.90% of the stock is owned by insiders.
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.